Artax Biopharma

Cambridge, MA · Founded 2013 · Privately Held (backing)

Developer of small-molecule drugs intended to treat autoimmune and inflammatory diseases. Artax Biopharma is based in Cambridge, MA and was founded in 2013. Its last reported valuation was $58 million in May 2022. It has raised $51.5 million across 8 recorded rounds; the latest was a $19 million early-stage round in Jul 2024.

Last reported valuation
$58.0M
Oct 2026
Priced at
—
Total raised
$51.5M
Last round
Early Stage VC
Jul 2024

Who backs Artax Biopharma?

9 investors
InvestorType
ABI LAB—
Advent Life Sciences—
Belinda Termeer—
Columbus Venture Partners—
Dosbio50—
Eli Lilly—
Henri Termeer—
Pappas Capital—
Sound Bioventures—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Artax Biopharma investors

9 investors are on record for Artax Biopharma, including ABI LAB, Advent Life Sciences, Belinda Termeer and Columbus Venture Partners. The early-stage round in Jul 2024 drew 30 investors.

Free account
More of Artax Biopharma with a free account
  • ·Watch Artax Biopharma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 9 firms already write checks for companies like Artax Biopharma. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View